Evidence map›Paper›PMID 36798271›Full record

ArticlebioRxiv : the preprint server for biology2023

Cell state transition analysis identifies interventions that improve control of

Shivraj M Yabaji, Oleksii S Rukhlenko, Sujoy Chatterjee, Bidisha Bhattacharya, Emily Wood, Marina Kasaikina, Boris Kholodenko, Alexander A Gimelbrant, Igor Kramnik

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Shivraj M YabajiThe National Emerging Infectious Diseases Laboratories (NEIDL), Boston University.
Oleksii S RukhlenkoSystems Biology Ireland, School of Medicine and Medical Science, University College Dublin, Belfield, Dublin 4, Ireland.
Sujoy ChatterjeeThe National Emerging Infectious Diseases Laboratories (NEIDL), Boston University.
Bidisha BhattacharyaThe National Emerging Infectious Diseases Laboratories (NEIDL), Boston University.
Emily WoodSystems Biology Ireland, School of Medicine and Medical Science, University College Dublin, Belfield, Dublin 4, Ireland.
Marina KasaikinaThe National Emerging Infectious Diseases Laboratories (NEIDL), Boston University.
Boris KholodenkoSystems Biology Ireland, School of Medicine and Medical Science, University College Dublin, Belfield, Dublin 4, Ireland.
Alexander A GimelbrantAltius Institute for Biomedical Sciences, Seattle, WA, USA.
Igor KramnikThe National Emerging Infectious Diseases Laboratories (NEIDL), Boston University.

Funding

Necrosis in pulmonary TB granulomas: dynamics, mechanisms, therapiesR01HL126066 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KRAMNIK, IGOR, NIEDERWEIS, MICHAEL · 2016 to 2025
$5.6M
Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway SignalingR01CA244660 · NCI · YALE UNIVERSITY · PI HLAVACEK, WILLIAM S, KHOLODENKO, BORIS N · 2020 to 2024
$3.4M
NCI NIH HHS R01 CA244660NHLBI NIH HHS R01 HL126066
6 · The paper itself

Abstract

Understanding cell state transitions and purposefully controlling them to improve therapies is a longstanding challenge in biological research and medicine. Here, we identify a transcriptional signature that distinguishes activated macrophages from TB-susceptible and TB-resistant mice. We then apply the cSTAR (cell State Transition Assessment and Regulation) approach to data from screening-by-RNA sequencing to identify chemical perturbations that shift the. transcriptional state of the TB-susceptible macrophages towards that of TB-resistant cells. Finally, we demonstrate that the compounds identified with this approach enhance resistance of the TB-susceptible mouse macrophages to virulent

Identifiers

PMID36798271
PMCPMC9934610

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.